SLN
Silence Therapeutics plc
NASDAQ · Healthcare · Biotechnology · GB
$14.59
−1.35%Year over year
Reported trailing growth
- Revenue
- -97.6%
- EBITDA
- +26.3%
- EBIT
- +29.8%
- EPS
- +31.4%
- Free cash flow
- +46.2%
- Operating cash flow
- +46.2%
Forward estimates
Based on analyst estimates
- Revenue
- +359.6%
- EBITDA
- +87.1%
- EPS
- +86.4%
Three-year CAGR
- Revenue
- -68.4%
- EBITDA
- -79.7%
- EBIT
- -41.7%
- Net income
- -95.6%
- EPS
- —
- Free cash flow
- -15.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026